Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Weighted Average) (2020 - 2025)

Arcutis Biotherapeutics has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $5.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $5.2 million for Q4 2025, down 95.69% from a year ago — trailing twelve months through Dec 2025 was $5.2 million (down 95.69% YoY), and the annual figure for FY2025 was $5.2 million, down 95.69%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $5.2 million at Arcutis Biotherapeutics, down from $126.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for ARQT hit a ceiling of $127.0 million in Q2 2025 and a floor of $5.2 million in Q4 2025.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $61.2 million (2023), compared with a mean of $75.7 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 94.92% in 2021 and later tumbled 95.69% in 2025.
  • Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) stood at $49.4 million in 2021, then grew by 11.39% to $55.0 million in 2022, then increased by 25.94% to $69.3 million in 2023, then soared by 74.53% to $121.0 million in 2024, then tumbled by 95.69% to $5.2 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $5.2 million (Q4 2025), $126.9 million (Q3 2025), and $127.0 million (Q2 2025) per Business Quant data.